Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,320 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Diseases Clear all
Completed Phase 1 Interventional

SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

NCT04050085
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Nivolumab, Radiation Therapy, TLR9 Agonist SD-101
Biological · Radiation · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 13, 2026, 2:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT06922591
View directory record Official record
Conditions
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
Interventions
TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Scottsdale, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Recruiting Phase 1 Interventional

Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07733674
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
203Pb-RMX-VHPIB injection, SPECT/CT Imaging
Drug · Diagnostic Test
Lead sponsor
Radiomedix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

NCT05131815
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
Interventions
Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 13, 2026, 2:14 AM EDT
Terminated Phase 1 Interventional

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

NCT06704724
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07985045, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Terminated Phase 1 Interventional

IGF-1 Therapy in Patients With Cystic Fibrosis

NCT00566241
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
recombinant human IGF-1, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 13, 2026, 2:14 AM EDT
Recruiting Phase 1 Interventional

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT07277413
View directory record Official record
Conditions
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions
IDE892, IDE397
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Not applicable Interventional

Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy

NCT00849979
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Questionnaire, Interview
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Airway Alkalinization and Nasal Colonization

NCT03078088
View directory record Official record
Conditions
Healthy Subjects, Cystic Fibrosis
Interventions
Tham, Saline
Drug
Lead sponsor
Lakshmi Durairaj
Other
Eligibility
16 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

NCT00185588
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Vatalanib, Gemcitabine
Drug
Lead sponsor
George Albert Fisher
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment

NCT00530686
View directory record Official record
Conditions
Islet Cell Transplantation, Type 1 Diabetes
Interventions
Islet cell transplantation
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 13, 2026, 2:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

NCT04327986
View directory record Official record
Conditions
Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer, Metastatic Pancreatic Cancer
Interventions
M7824, M9241, SBRT
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 3 Interventional

Acupuncture For Pancreatic Cancer Pain

NCT00136669
View directory record Official record
Conditions
Pancreatic Neoplasms, Pain
Interventions
Acupuncture
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2006 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

NCT02950805
View directory record Official record
Conditions
Pulmonary/Respiratory Diseases
Interventions
Placebo, AZD5634
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 13, 2026, 2:14 AM EDT
Recruiting Phase 1 Interventional

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697
View directory record Official record
Conditions
Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms
Interventions
cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing
Drug · Biological · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Completed No phase listed Observational

Fecal Calprotectin in Cystic Fibrosis

NCT00863694
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Month and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

NCT00019331
View directory record Official record
Conditions
Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 13, 2026, 2:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Kidney Function in People With Cystic Fibrosis in the Era of HEMT

NCT06595420
View directory record Official record
Conditions
Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Acute Kidney Injury
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
7 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Lebanon, New Hampshire • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Terminated Phase 1Phase 2 Interventional

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

NCT02605083
View directory record Official record
Conditions
Cancer
Interventions
eFT508
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 13, 2026, 2:14 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer

NCT04400903
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8
Interventions
Activity Monitor, Quality-of-Life Assessment, Questionnaire Administration
Device · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
50 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Omaha, Nebraska • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Radiation to Decrease Pancreatic Secretions

NCT01656486
View directory record Official record
Conditions
Pancreatic Fistulae
Interventions
Stereotactic Radiation
Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 13, 2026, 2:14 AM EDT
Completed No phase listed Observational Results available

Evaluation of Pancreatic Pseudocyst Drainage With a Metal Stent

NCT01239056
View directory record Official record
Conditions
Pancreatic Pseudocysts
Interventions
Endoscopy
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 13, 2026, 2:14 AM EDT
Recruiting Phase 3 Interventional

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

NCT06807437
View directory record Official record
Conditions
Pancreatic Carcinoma, Pancreatic Neoplasm
Interventions
Biospecimen Collection, Distal Pancreatectomy, Lanreotide, Questionnaire Administration, Saline
Procedure · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
118
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Terminated Phase 1 Interventional

A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

NCT02908451
View directory record Official record
Conditions
Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Cancer
Interventions
AbGn-107
Biological
Lead sponsor
AbGenomics B.V Taiwan Branch
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 13, 2026, 2:14 AM EDT